

Review Article

Essential Oils and Their Major Compounds in the Treatment of Chronic Inflammation: A Review of Antioxidant Potential in Preclinical Studies and Molecular Mechanisms

Érica Martins de Lavor,¹ Antônio Wilton Cavalcante Fernandes,¹ Roxana Braga de Andrade Teles,¹ Ana Ediléia Barbosa Pereira Leal,¹ Raimundo Gonçalves de Oliveira Júnior ^(b),² Mariana Gama e Silva,¹ Ana Paula de Oliveira,¹ Juliane Cabral Silva,¹ Maria Tais de Moura Fontes Araújo,¹ Henrique Douglas Melo Coutinho ^(b),³ Irwin Rose Alencar de Menezes ^(b),³ Laurent Picot,² and Jackson Roberto Guedes da Silva Almeida ^(b)

¹Center for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, 56304-205 Petrolina, Pernambuco, Brazil

²UMRi CNRS 7266 LIENSs, University of La Rochelle, La Rochelle, France

³Department of Biological Chemistry, Regional University of Cariri, 63105-000 Crato, Ceará, Brazil

Correspondence should be addressed to Jackson Roberto Guedes da Silva Almeida; jackson.guedes@univasf.edu.br

Received 28 June 2018; Accepted 1 November 2018; Published 23 December 2018

Academic Editor: Demetrios Kouretas

Copyright © 2018 Érica Martins de Lavor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory diseases result from the body's response to tissue damage, and if the resolution is not adequate or the stimulus persists, there will be progression from acute inflammation to chronic inflammation, leading to the development of cancer and neurodegenerative and autoimmune diseases. Due to the complexity of events that occur in inflammation associated with the adverse effects of drugs used in clinical practice, it is necessary to search for new biologically active compounds with antiinflammatory activity. Among natural products, essential oils (EOs) present promising results in preclinical studies, with action in the main mechanisms involved in the pathology of inflammation. The present systematic review summarizes the pharmacological effects of EOs and their compounds in *in vitro* and *in vivo* models for inflammation. The research was conducted in the following databases: PubMed, Scopus, BIREME, Scielo, Open Grey, and Science Direct. Based on the inclusion criteria, 30 articles were selected and discussed in this review. The studies listed revealed a potential activity of EOs and their compounds for the treatment of inflammatory diseases, especially in chronic inflammatory conditions, with the main mechanism involving reduction of reactive oxygen and nitrogen species associated with an elevation of antioxidant enzymes as well as the reduction of the nuclear factor kappa B (NF- κ B), reducing the expression of proinflammatory cytokines. Thus, this review suggests that EOs and their major compounds are promising tools for the treatment of chronic inflammatory.

1. Introduction

Inflammation is characterized as a normal response to tissue damage caused by several potentially injurious stimuli, induced by biological, chemical, and physical factors [1]. Initially, inflammatory agents elicit an acute inflammatory response which generally promotes complete destruction of the irritants. This type of inflammation persists for a short time and is beneficial for the host [2, 3]. However, if resolution of inflammation is inadequate or the stimulus persists,

chronic inflammation occurs, predisposing the host to various diseases including, for example, cancer and neurodegenerative diseases [4–6].

During chronic inflammation, a variety of intracellular signaling pathways are activated, comprising of cell surface receptors, tyrosine kinases, and transcription factors, leading to overexpression of proinflammatory genes involved in the development of chronic diseases [2]. Furthermore, the cellular components represented by the mast cells and leukocytes are recruited to the site of the damage, which leads to a "respiratory burst" result of increased oxygen uptake and therefore an increased release and accumulation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) at the site of damage [2, 4-7]. Under physiological conditions, ROS are generated in phagocytes to neutralise the invading organisms, presenting an important role in the host defense mechanism. In contrast to oxidant mechanisms, the organism has endogenous defense antioxidant systems, including for example superoxide dismutase, glutathione peroxidase, and catalase. When ROS production is greater than cellular antioxidant capacity, oxidative stress can damage DNA, proteins, and lipids [8-11].

A diversity of protein kinases is activated in the inflammatory process, such as members of the Janus-activated kinase (JAK), phosphatidylinositol-3-kinase (PI3K/, AKT), and mitogen-activated protein kinase (MAPK) families to alter cell proliferation. In the chronic inflammatory process, the excessive activation of these signaling pathways causes also the activation of certain transcription factors, such as NF- κ B, signal transducer and activator of transcription 3 (STAT3), hypoxia-inducible factor-1 α (HIF1- α), and activator protein-1 (AP-1), potentiating the initial inflammatory response. In addition to these factors, the cyclooxygenase enzyme (COX), inducible nitric oxide synthase (iNOS), cytokines, and chemokines have also been reported to play a role in oxidative stress-induced inflammation [2, 12, 13].

In recent years, the search for more effective drugs for the treatment of the inflammation with fewer side effects has encouraged researchers to study and develop new drugs. The search for natural products derived from plants is a promising reality, and among the substances with pharmacological potential we can cite the essential oils (EOs).

EOs are liquid mixtures of volatile compounds obtained from aromatic plants, which represent a small fraction of the plant composition [14]. However, they are responsible for providing characteristics that favor their use in the food, cosmetic, and pharmaceutical applications. Essential oils have a complex composition; the great majority of the identified components include terpenes (oxygenated or not), predominantly monoterpenes and sesquiterpenes. However, allyl and propenylphenols (phenylpropanoids) also are important components of some essential oils [15–17]. These secondary metabolites have been related as potent antioxidants, free radical scavengers, and metal chelators, also presenting antinociceptive, neuroprotective, anticonvulsant, and anti-inflammatory properties, reported in preclinical studies, characterizing as potential source for the development of new drugs [17-20].

The objective of this review was to relate the use of essential oils correlating its antioxidant effect in the treatment of chronic inflammations.

2. Material and Methods

2.1. Search Strategy. In this review, the specialized databases PubMed, Science Direct, Scopus, Open Grey, Scielo, and BIREME were used for literature search in March and April 2018, using different combinations of the following keywords: essential oils, volatile oils, antioxidants, and inflammation. We did not contact investigators, and we have not attempted to identify unpublished data until the date of the search.

2.2. Study Selection. In this step, two independent researchers (J.C.S. and A.W.C.F.) first selected the articles according to title and abstract and finally through an analysis of the full-text publication. The following inclusion criteria were applied: studies with EOs or their major compounds with anti-inflammatory and antioxidant activity *in vitro* and/or *in vivo*. Studies were excluded according to the following exclusion criteria: review articles, meta-analyses, abstracts, conference proceedings, editorials/letters, case reports and studies in humans, and articles published over 20 years ago. Additional papers were included in our study after analyses of all references from the selected articles. In cases of nonconsensus, a third independent review was consulted (E.M.L.) for final decision.

2.3. Data Extraction. Data were collected and examined by one reviewer using standardized forms and were checked by a second reviewer. The information extracted from the articles included EOs or their major compounds, cell lines (*in vitro* studies), animal models (*in vivo* studies), doses or concentrations, routes of administration, biochemical assays, and molecular mechanisms investigated.

2.4. Methodological Quality Assessment. The risk of bias and quality of preclinical *in vivo* studies were performed using an adapted checklist [21–23]. This investigation allowed assessing the methodological quality of the included studies concerning mainly the randomization of the treatment allocation, blinded drug administration, blinded outcome assessment, and outcome measurements.

3. Results and Discussion

3.1. Study Selection. The primary search identified 429 articles (200 from Scopus, 18 from Science Direct, 32 from BIREME, and 179 from PubMed). However, 146 manuscripts were indexed in two or more databases and considered only once, resulting in 283 original articles. After an initial screening of titles and abstracts, 192 articles were excluded because they did not meet the inclusion criteria or presented completely different themes from the proposal of this review. After an initial screening of titles were considered potentially relevant. In addition, 3 articles were included after manual search for data extraction, totalizing 30 final articles



FIGURE 1: Flowchart detailing literature searching and screening.

included in this systematic review. A flowchart illustrating the progressive study selection and numbers at each stage is shown in Figure 1.

3.2. Characteristics of Included Studies. The selected final articles were carefully analyzed in relation to the country where the study was conducted, year of publication, family of the studied species, and whether the study was carried out with essential oils or substances obtained from them. Table 1 summarizes general information contained in the selected *in vitro* and *in vivo* studies.

Studies were conducted by research groups located in about 13 different countries. Most of the investigations were authored by researchers from Brazil (7 reports, 24.13%), China (6 reports, 20.68%), and India (5 reports, 17.24%).

The largest number of studies found in Brazil is justified by the fact that Brazil has an extremely rich biodiversity, corresponding to approximately 20% of all living species known globally, comprising over 45,000 species of higher plants. In addition, the Brazilian population has a historical tradition in the use of medicinal plants for the treatment of different diseases, including acute and/or chronic inflammation disorders [54, 55]. Another interesting fact is the number of studies conducted in China and India, which may be justified as a reflection of the contribution of Oriental medicine in the search and development for new drugs from natural products. In fact, traditional Chinese medicine (TCM) and Ayurveda as major traditional treatment systems used not only in India and China but also in several countries contributed to the development of new pharmaceutical products based on plant species [56–58].

Regarding the number of annual publications, we noted that a large number of articles were published from 2010 to 2015 (12 reports). Only in the last three years were 18 studies (62.02%) found, suggesting that the involvement of oxidative stress in anti-inflammatory activity of essential oils or their major compounds has attracted the attention of the researchers in diverse regions of the world. These results are graphically presented in Figure 2.

Among the included articles, only 10 (32.25%) corresponded to studies with isolated components of essential oils, demonstrating that reports involving EOs are still predominant in this subject. Of these oils, three studies were reported for species belonging to the Rutaceae family and two studies for the families Zingiberaceae, Apiaceae, Cupressaceae, and Lamiaceae. The other studies correspond to other families reported in Table 1.

As described in Table 1, our review included 2 reports presenting in *vitro* and *in vivo* studies, 9 reports presenting only *in vitro* studies, and 19 reports presenting only *in vivo* studies. In the studies reported in this review, biochemical and molecular targets were verified by colorimetric and enzymatic assays, biochemical analyses, and techniques such as Western blot and immunohistochemistry. These studies base their assays on methodologies using cell culture commonly found in chronic inflammatory processes, such as macrophages, monocytes, astrocytes, and cancer cells, correlating anti-inflammatory results with the antioxidant potential of

Authors, year, country	Model	Essential oil	Major constituents	Family	Induction of inflammation	Type of inflammation
Tsai et al., 2011, Taiwan [24]	In vitro	Essential oils of the aerial parts of Eucalyptus bridgesiana, Cymbopogon martinii, Thymus vulgaris, Lindernia anagallis, and Pelargonium fragrans	1,8-Cineole Geraniol Thymol <i>p</i> -Menthanone (–)-Spathulenol	Myrtaceae Poaceae Lamiaceae Linderniaceae Geraniaceae	Lipopolysaccharide (LPS) from <i>Escherichia</i> <i>coli</i> and heat-killed <i>Propionibacterium</i> <i>acnes</i>	Inflammation induced by biological agent
Ritter et al., 2013, Brazil [25]	In vivo	Ι	Anethole	I	Complete Freund's adjuvant	Inflammation induced by biological agent
Jeena et al., 2013, India [26]	In vivo	Essential oil of ginger	Zingiberene	Zingiberaceae	Formalin	Inflammation induced by chemical agent
El-Readi et al., 2013, Egypt [27]	In vitro	Essential oils from leaves and stems of <i>Liquidambar</i> styraciflua	α-Pinene	Altingiaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Valente et al. 2013, Portugal [28]	In vitro	Essential oils of the aerial parts of <i>Oenanthe crocata L</i> .	β -Ocimene Sabinene	Apiaceae	LPS from <i>Escherichia</i> coli and INF-γ	Inflammation induced by biological agent
Lin et al., 2014, China [29]	In vitro	Essential oil of <i>Patrinia</i> scabiosaefolia	Caryophyllene oxide	Caprifoliaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Destryana et al., 2014, Indonesia [30]	In vitro	Essential oil from leaf and branches of <i>Ocotea quixos</i> , wood, branches, and leaves of <i>Callitris intratropica</i> and <i>Copaifera reticulata</i> <i>langsdorffii</i> gum-resin	trans-Caryophyllene β -Caryophyllene (+)-Calarene	Lauraceae Cupressaceae Fabaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Shirole et al., 2014, India [31]	In vitro and in vivo	Essential oil of <i>Pistacia</i> integerrima	4-Carvomenthenol	Anacardiaceae	LPS from <i>Escherichia</i> coli and ovalbumin	Inflammation induced by biological agent
Patil et al. 2014, India [32]	In vivo	Essential oil of <i>Camellia</i> <i>reticulata</i> L.	I	Theaceae	Indomethacin	Inflammation induced by chemical agent
Khodabakhsh et al. 2014, Japan [33]	In vivo	Essential oil from blossoms of <i>Citrus aurantium</i> L.	Linalool	Rutaceae	Cotton pellet—subcutaneous	Inflammation induced by physical agent
Wu et al., 2014, China [34]	In vivo	I	Linalool	I	Pasteurella multocida intranasal	Inflammation induced by biological agent
Jeena et al., 2014, India [35]	In vivo	Essential oil of <i>Piper nigrum</i> Linn	Caryophyllene	Piperaceae	Formalin	Inflammation induced by chemical agent
Entok et al., 2014, Turkey [36]	In vivo	Essential oil of <i>Nigella</i> sativa L.	I	Ranunculaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Kazemi 2015, Iran [37]	In vitro	Essential oils of Achillea millefolium L., Anethum graveolens L., and Carum copticum L.	Thymol	Asteraceae Apiaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent

TABLE 1: General characteristics of included studies (in vitro and in vivo reports).

I

4

Oxidative Medicine and Cellular Longevity

		TABLE 1. CO				
Authors, year, country	Model	Essential oil	Major constituents	Family	Induction of inflammation	Type of inflammation
Pinheiro et al., 2015, Brazil [38]	In vivo	Essential oil from leaves of Choisya ternata Kunth	I	Rutaceae	Dorsal subcutaneous injection of sterile air and carrageenan suspension	Inflammation induced by chemical agent
Kara et al. 2015, Turkey [39]	In vivo	I	Carvacrol	I	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Allam et al. 2015, Egypt [40]	In vivo	Essential oil of thyme	Ι	Lamiaceae	Shigella flexneri	Inflammation induced by biological agent
Shen et al. 2016, China [41]	In vitro	Essential oil of calyx of Hibiscus sabdariffa L.	<i>n</i> -Hexadecanoic acid	Malvaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Park et al., 2016, Korea [42]	In vitro and in vivo	Essential oil of Chamaecyparis obtusa	I	Cupressaceae	In vitro: LPS from Escherichia coli In vivo: carrageenan- induced paw edema, thioglycollate-induced peritonitis	Inflammation induced by biological and chemical agent
Skala et al., 2016, Poland [43]	In vitro	Essential oils from roots of Rhaponticum carthamoides	Cyperene Aplotaxene	Asteraceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Zhao et al., 2016, China [44]	In vivo	Ι	Cinnamaldehyde	I	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Yu et al., 2016, Brazil [45]	In vivo	Ι	Thymol	I	High-fat-diet-induced hyperlipidemia and atherosclerosis.	Inflammation induced by chemical agent
Kennedy-Feitosa et al. 2016, Brazil [46]	In vivo		Eucalyptol	I	Exposition to commercial cigarettes	Inflammation induced by chemical agent
Alvarenga et al. 2016, Brazil [47]	In vivo	I	Carvacrol		Irinotecan	Inflammation induced by chemical agent
Shen et al., 2017, China [48]	In vitro	Essential oil from blossoms of <i>Citrus aurantium</i>	I	Rutaceae	LPS from <i>Escherichia</i> coli	Inflammation induced by biological agent
Liu et al., 2017, China [49]	In vivo	Ι	eta-Elemene	I	High-fat-diet-induced hyperlipidemia and atherosclerosis	Inflammation induced by chemical agent
Leelarungrayub et al. 2017, Thailand [50]	In vivo	Essential oil of <i>Zingiber</i> <i>cassumunar</i> Roxb. in niosomes entrapped	Terpinen-4-ol	Zingiberaceae	LPS from Porphyromonas gingivalis	Inflammation induced by biological agent
Arigesavan and Sudhandiran 2017, India [51]	In vivo	Ι	Carvacrol	I	1,2-Dimethylhydrazine (DMH) and dextran sodium sulphate (DSS)	Inflammation induced by chemical agent

TABLE 1: Continued.

Oxidative Medicine and Cellular Longevity

Type of inflammation	Inflammation induced by biological agent	Inflammation induced by chemical agent
Induction of inflammation	LPS from <i>Escherichia</i> coli	Imiquimod
Family	I	I
Major constituents	l-Carveol, l-carvone, <i>m</i> -cymene, valencene, and guaiene	Thymol in nanoparticles from natural lipids
Essential oil	I	I
Model	In vitro	In vivo
Authors, year, country	Marques et al., 2018, Brazil [52]	Pivetta et al. 2018, Brazil [53]

TABLE 1: Continued.



FIGURE 2: Distribution of the selected studies by country (a) and year of publication (b).

essential oil or their major components. The evaluated *in vitro* studies parameters and main outcomes are summarized in Table 2 and *in vivo* studies in Table 3.

3.3. Methodological Quality of In Vivo Studies. Regarding methodological quality, all *in vivo* studies were evaluated using a standardized checklist, as shown in Figure 3. It was observed that all studies described the objectives, outcomes to be measured, and main findings obtained. However, none of the included articles reported sample size calculation. In general, doses, routes of administration, and frequency of treatment were adequately described. Most of the *in vivo* studies (18 reports, 85.7%) adequately reported the animal allocation, but less than half (10 reports, 47.6%) reported that the animals were randomly housed. In addition, the majority of included studies did not make it clear if the investigators or the outcome assessor were blinded from the treatment used.

The number of animals to be used, randomization, and blinding are important steps in preclinical protocols in order to reduce the risk of bias and improve translatability of animal research [59, 60]. In this way, the evaluation of the methodological quality indicated that the majority of *in vivo* studies included in this review present moderate quality, which limits the interpretation of the results.

3.4. In Vitro Tests of Anti-inflammatory Activity. Researchers, when proposing to investigate the pharmacological evaluation of substances, initially carry out *in vitro* tests, since these tests present a high reproducibility and function as a trait to evaluate the pharmacological potential of these substances, as for example the anti-inflammatory activity. The assays employed are, in most instances, cell culture techniques, in which the cells receive various stimuli (chemical or biological) that induce the production of mediators involved in inflammatory processes, such as arachidonic acid and cytokines and their metabolites [24, 28, 30, 42].

In the majority of *in vitro* selected papers, the antiinflammatory activity tests employed the macrophage cell line RAW 264.7 activated by LPS [28, 30, 41, 42, 48]. Macrophages play a critical role in the inflammatory process through the production of various cytokines. When these cells are activated, they express the inflammatory enzymes (iNOS and COX-2) and proinflammatory cytokines (TNF- α and IL-6). However, they also may play an antiinflammatory role in which they express IL-4, IL-13, or IL-10 cytokines [61–63].

Other cells participate in the inflammatory process and have a crucial role in the development of inflammatory diseases. To evaluate this activity, Singh et al. [64] proposed the utilization of the human THP-1 cell, a common model to estimate modulation of monocyte and macrophage activities. Circulating monocytes have the potential to differentiate into tissue macrophages, providing help in the phagocytosis of invading pathogens, reducing tissue aggression by potentially harmful agents [65].

In recent years, inflammatory processes have been correlated to the development of chronic diseases. However, chronic inflammation and cytokine dysfunction are associated with conditions such as cancer progression, cardiovascular disease, diabetes, and neurodegenerative disease [66]. To better study these molecular aspects, inflammatory models using microglial [29] and astrocyte [43] cell lines have been used to evaluate the influence of inflammatory processes on the development of neurodegenerative diseases and tumor cell lines such as HepG2 [27] to evaluate the relationship between the processes inflammatory and malignant neoplasms.

3.5. Animal Models in Chronic Inflammation. Chronic inflammation is an aggravating factor for tissue damage, commonly present in many chronic diseases, including asthma, obstructive pulmonary disease, and neuroinflammatory and autoimmune disorders [67]. For this reason, it is necessary to understand the molecular mechanisms involved in the inflammatory process in order to develop new treatment and prevention protocols. Thus, many experimental models have been developed, most often using mice and rats, in order to correlate the pathophysiology of the disease and to aid in the development of new drugs [68, 69].

Concerning *in vivo* studies included in this review, EOs were investigated in experimental models of ulcerative enterocolitis; lesions developed by chemotherapeutic agents; peritoneal, subcutaneous, pulmonary, and cardiac

Essential oil and/or majority constituent	Doses	Antioxidant and anti- inflammatory assays	Cell line	General results and proposed mechanism of action	Reference
Essential oils of the aerial part of <i>Eucalyptus</i> bridgesiana, <i>Cymbopogon</i> martinii, <i>Thymus vulgaris</i> , Lindernia anagallis, and Pelargonium fragrans	0.01 µg/mL	β -Carotene linoleic acid bleaching test, DPPH radical, and nitric oxide scavenging assay 5-LOX inhibition assay Measurement of IL-1 β , IL-8, TNF- α	THP-1 (human mylomonocytic cell)	Strong antioxidant activity in the tests performed; inhibition of 5-LOX activity and reduction of IL-1 β , IL-8, and TNF- α secretion in THP-1 cells	Tsai et al. 2011 [24]
Essential oils of the aerial parts of <i>Oenanthe crocata</i> L., β-ocimene, or sabinene	EO: 0.08, 0.16, and 0.32 μL/mL β-Ocimene and sabinene: 0.32-1.25 μL/mL	Measurement of NO, Western blot analysis for iNOS, and nitric oxide scavenging activity	RAW 264.7 macrophages	Strong NO scavenging activity and inhibition of iNOS expression Sabinene exhibited NO scavenging activity only at higher concentrations	Valente et al. 2013 [28]
Essential oils from leaves and stems of <i>Liquidambar</i> Styraciflua	1, 10, 100 and 500 $\mu g/mL$	5-LOX and PGF ₂ inhibition DPPH radical and superoxide scavenging activity	HepG-2 cells	Reduction of DPPH, (OH [•]), and (O ₂ [•]) radicals Inhibition of 5-LOX and PGE ₂	El-Readi et al. 2013 [27]
Essential oil of Patrinia scabiosaefolia	50, 100, 150, 200, and 250 µg/mL	Measurement of IL-1 and IL-6 DPPH radical scavenging assay	BV-2 cell (microglia)	Inhibition of the production of IL-1 and IL-6; scavenging activity against the DPPH radical	Jing et al. 2014 [29]
Essential oil from leaf and branches of <i>Ocotea quixos</i> , wood, and branches and leaves of <i>Callitris</i> <i>intratropica</i> and <i>Copaifera</i> <i>reticulata/langsdorffii</i> gum-resin	5, 10, an 20 <i>µ</i> g/mL	β -Carotene linoleic acid bleaching test and DPPH radical scavenging assay Measurement of NO production Western blotting analyses for the iNOS and COX-2 and measurement of IL-8, IL-6, and IL-1 β	RAW 264.7 macrophages	The EO of <i>O. quixos</i> and <i>C.</i> reticulata did not possess an antioxidant activity, while Blue Cypress possessed a moderate antioxidant activity Only Ocotea suppress the LPS-induced PGE ₂ production, LPS-mediated iNOS, and COX-2 elevation Suppression of LPS- stimulated IL-8 and IL-1 β production in the cells	Destryana et al. 2014 [30]
Essential oils of Achillea millefolium L., Anethum		DPPH radical scavenging and FRAP assay	RAW 264.7 macrophages	A. millefolium had the highest antioxidant activity	Kazemi 2015, Iran [37]

TABLE 2: In vitro studies involving essential oils, anti-inflammatory and antioxidant activity.

8

Essential oil and/or majority constituent	Doses	Antioxidant and anti- inflammatory assays	Cell line	General results and proposed mechanism of action	Reference
graveolens L., and Carum copticum L.		eta-Carotene bleaching test Determination of NO production.		in all conducted assays and inhibited nitric oxide production	
Essential oil of calyx of Hibiscus sabdariffa L.	25, 50, 100, 200, and 300 µg/mL	Determination of NO production Measurement of cytokines Production (IL-1 and IL-6) RT-PCR assay of IL-1, IL-6, TNF-α, iNOS, and COX-2 mRNA Western blot analyses for the p-JNK, p-ERK1/2, NF- <i>κ</i> B, and GAPDH	RAW 264.7 macrophages	Inhibition of NF- <i>k</i> B signaling pathways and MAPK (JNK and ERK1/2), reduction of NO production and IL-1, IL-6, TNF- <i>a</i> , COX-2, and iNOS	Shen et al. 2016 [41]
Essential oil of Chamaecyparis obtusa	<i>In vitro</i> : 1, 10, 50 and 100 μg/mL <i>In vivo</i> : 5 and 10 mg/kg	<i>In vitro</i> : measurement of NO, IL-1β, TNF-α, and IL-6 by levels; Western blot analyses for expression of iNOS and COX-2 <i>In vivo</i> : carrageenan-induced paw edema and thioglycollate- induced peritonitis	RAW 264.7 macrophages	Decreasing in the number of total cells and suppression of TNF- α , IL-1 β , and IL-6 levels in peritoneal fluid Suppression of iNOS and COX-2 expression	Park et al. 2016 [42]
Essential oils from roots of Rhaponticum carthamoides	25, 50, and 100 μg/mL	Measurement of cytokines IL-1β, IL-6, IL-8, IL-10, TNF-α, and GM-CSF and RT-PCR. ROS formation assay using H2DCF-DA.	Human astrocytes	Decreasing the expression of IL-1 β , IL-6, and TNF- α and the ROS level	Skala et al. 2016 [43]
Essential oil from blossoms of <i>Citrus</i> aurantium	15.625, 31.25, 62.5, 125, and 250 µg/mL	DPPH and ABTS radical scavenging activity Determination of morphology and NO production. Quantification of IL-6, TNF- α , and IL-1 β Reverse transcription and PCR-RT for iNOS	RAW 264.7 macrophages	Did not show scavenging effects on DPPH and ABTS radicals Inhibition of NO accumulation and suppression of IL-6, TNF- α , and IL-1 β secretion Inhibition of the expression of COX-2 and NF- κ B activation Involvement of the	Shen et al. 2017 [48]

		TABLE 2: C	ontinued.		
Essential oil and/or majority constituent	Doses	Antioxidant and anti- inflammatory assays	Cell line	General results and proposed mechanism of action	Reference
				inflammation process through MAPK signaling pathways, by inhibiting phosphorylation of JNK (c-Jun N-terminal kinase) and p38	
l-Carveol, l-carvone, <i>m</i> -cymene, valencene, and guaiene	1, 10, and 100 μM	Protective effect against oxidative damage produced by superoxide anion production (O_2^{-1}) and hydrogen peroxide Determination of NO production Quantification of IL-1 α , TNF- α , and IL-10 Activity of NF- κ B	RAW 264.7 macrophages	Reduction in TNF- α and IL-1 α levels and increasing in the production of IL-10 Guaiene and <i>m</i> -cymene inhibited NO production I-Carveol and <i>m</i> -cymene significantly inhibited O ₂ ⁻¹ production Terpenes suppressed NF- κ B activity	Marques et al. 2018 [52]
EO: essential oil; NO: nitric oxid ABTS: 2,2'-azino-bis(3-ethylben interleukin-10; FRAP: ferric redu lipoxygenase; PGE2: prostagland	e; ROS: reactive oxygen speci zothiazoline-6-sulphonic aci icing antioxidant power; MP in E2; MAPK: mitogen-activ	ies; iNOS: inducible nitric oxide synthase; II d); NF-κB: nuclear factor kappa B, COX-2 O: myeloperoxidase; PCR-RT: real-time que ated protein kinases; GAPDH: glyceraldehyc	 -1β: interleukin-1 beta; DPPH: 2,2- : cyclooxygenase; TNF-α: tumor no initative polymerase chain reaction le 3-phosphate dehydrogenase. 	diphenyl-1-picrylhydrazyl radical; LF ecrosis factor alpha; IL-6: interleuki ; H2DCF-DA: 2',7'-dichlorodihydro	PS: lipopolysaccharide; M: male; in-6; IL-8: interleukin-8; IL-10: ofluorescein diacetate; 5-LOX: 5,

		TABLE 3: In vivo studie	es involving essential oils and	antioxidant activity.		
Essential oil and/or majority constituent	Animals (strain/sex), n (per group)	Doses, route, and administration period	Antioxidant assays	Experimental model of inflammation	General results	Reference
Essential oil of ginger	Mice (Balb/c/), $n = 3, 5$, or 6	10, 50, 100, 250, 500, or 1000 mg/kg (i.p. or p.o.), single dose or 4 days	Lipid peroxidation, SOD and hydroxyl activity assay DPPH and ABTS radical scavenging and FRAP assay PMA-induced radical generation and dosage of SOD, CAT, and GSH <i>in vivo</i>	Formalin induced chronic inflammation	Scavenged superoxide, DPPH, hydroxyl radicals, and lipid peroxidation inhibition Increase in SOD, GSH, and GR enzyme levels in blood and glutathione peroxidase and SOD enzymes in liver Reduction in formalin- induced chronic inflammation	Jeena et al. 2013 [26]
Anethole	Mice (Swiss/M), $n = 6$	125, 250, or 500 mg/kg (p.o.), for until 7 days	MPO activity	Paw edema induced by complete Freund's adjuvant	Inhibition of paw edema on all of the days analyzed Inhibition of MPO activity and reduction of TNF- α , IL-1 β , and IL-17 levels in acute and persistent inflammation models	Ritter et al. 2013 [25]
Essential oil of Nigella sativa L.	Rats (Sprague–Dawley), $n = 7$	500 mg/kg (p.o.), 3 times a 1 day	Determination of SOD, CAT activity, and MDA and NO levels	LPS induced inflammation	Increase in SOD and CAT, and reduction of MDA and NO in lung	Entok et al. 2014 [36]
Essential oil of <i>Piper</i> <i>nigrum</i> Linn	Mice (Balb/C), $n = 5$ or 6	10, 50, 100, 250, 500, or 1000 mg/kg (i.p. or p.o.), 5 or 30 days.	Lipid peroxidation and SOD and hydroxyl activity assay DPPH radical scavenging and FRAP assay PMA-induced radical generation and dosage of SOD, CAT, and GSH <i>in vivo</i>	Formalin induced chronic inflammation	Scavenged SOD, DPPH, and hydroxyl radicals; inhibition of lipid peroxidation <i>in vitro</i> Increase in SOD and GSH enzyme levels in blood of mice and CAT, SOD, and GSH enzymes in liver Reduction of chronic inflammation in formalin test	Jeena et al., 2014 [35]
Linalool	Mice (C57BL/6J/M), $n = 10$	5, 15 or 25 mg/kg (s.c.)	ROS and SOD activity assay	Pasteurella multocida induced intranasal lung infection/ inflammation	Increase in nuclear Nrf-2 protein amount and reduction in SOD expression Reduction in TNF-α and IL-6 levels and decrease in neutrophil accumulation	Wu et al. 2014 [34]
	Rats (Wistar/M), $n = 8$		Measurement of NO	Cotton pellet-induced granuloma	Decrease in transudate and granuloma formation	Khodabakhsh et al. 2014 [33]

			TABLE J. COMMINCO.			
Essential oil and/or majority constituent	Animals (strain/sex), n (per group)	Doses, route, and administration period	Antioxidant assays	Experimental model of inflammation	General results	Reference
Essential oil from blossoms of <i>Citrus</i> aurantium L.		5, 10, 20, 40, or 80 mg/kg (i.p.) for until 7 days			amount involving the nitric oxide pathway	
Essential oil of Camellia reticulata L.	Rats (Wistar/M), $n = 6$	200 or 400 mg/kg (p.o.) for 11 days	Colonic GSH content and lipid peroxides concentration	Enterocolitis induced by indomethacin	Decrease in macroscopic and microscopic scores for inflammation Reduction in MPO and lipid peroxidation and increase in GSH content	Patil et al., 2014 [32]
Essential oil of Pistacia integerrima	Rats (Sprague-Dawley/F), n = 6	5-30 μg/mL; 10, 30, or 100 mg/mL; and 7, 5, 15, or 30 mg/kg (i.p.)	DPPH radical scavenging, lipoxygenase activity, and measurement of NO and MPO	LPS- and ovalbumin- induced bronchial inflammation	Inhibition of lipoxygenase enzyme and DPPH scavenging activity Antiallergic activity by inhibition of mast cell degranulation Reduction in total leucocyte, neutrophils, NO, total protein, and albumin levels in bronchoalveolar fluid and MPO levels in lung homogenates	Shirole et al. 2014 [31]
Essential oil of thyme	Rats (Sprague-Dawley/M), $n = 25$	7, 5, 15, or 30 mg/kg (i.p.) for 21 days	FRAP assay	Ulcer-forming induced by <i>Shigella</i> <i>flexneri strain</i>	Synergistic activity of thyme oil decreased the inflammation of the lamina propria and decreased the bacterial load in the colon Increase in total antioxidant capacity time	Allam et al. 2015 [40]
Essential oil from leaves of <i>Choisya</i> <i>ternata</i> Kunth	Mice (Webster/M), $n = 4, 6$, 8 or 10	3-10 or 30 mg/kg (p.o.)	NO levels and trapping capacity of anthranilates	Formalin test and subcutaneous air pouch (SAP) model	Reduction in migration, exudate volume, and protein extravasation and reduced levels of NO, TNF-α, and IL-1β	Lin et al. 2014 [29]
Carvacrol	Rats (Sprague-Dawley/F), n = 6, 7, or 8	20, 40, or 80 mg/kg (p.o.) for 6 days	MDA and NO levels	LPS-induced peritoneal inflammation	Decrease in levels of TNF- α and IL-6, MDA, NO levels, and arginase activity levels	Kara et al., 2015 [39]
Cinnamaldehyde	Rats (Sprague-Dawley/M), $n = 6$	30, 60, or 90 (p.o.) 1x/day for 30 days	Determination of intracellular levels of ROS	LPS-induced cardiac dysfunction	Inhibition of cardiac dysfunction, inflammatory influration, and the levels of TNF- α , IL-1 β , and IL-6 in LPS stimulated rats by	Zhao et al., 2016 [44]

TABLE 3: Continued.

12

(straii rr grou
n = 6 3 or 6 mg/kg (p.o) for 8 weeks
$M, n = 8 \qquad \text{inhalation (15 min/daily) for 5 days}$
i = 5 or 8 25, 75, or 150 mg/kg (i.p.) for 8 days
7BL/6/M), Not related
50 mg/kg (p.o.) for 7 M), $n = 6$ days before and 7 days, after tumor induction

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							
intermediationvitamin C, and NO levelproinflammatory mediators iNOS and IL-1 β and MDA contentsReduction in ulcer size Inhibition of DPH radical and decrease in skinand interventLPS-inducedInhibition of DPH radical and decrease in skinand interventInhibition of DPH radicaland blockInhibition of DPH radicaland blockInhibition of DPH radical	r nt	Animals (strain/sex), n (per group)	Doses, route, and administration period	Antioxidant assays	Experimental model of inflammation	General results	Reference
$ In Michae (Mistar/M), n = 5 12.5-400 \ \mu g/mL $ $ In Michae (Mistar/M), n = 5 12.5-400 \ \mu g/mL $ $ In Michae (Mistar/M), n = 5 12.5-400 \ \mu g/mL $ $ In Michae (Mistar/M), n = 5 12.5-400 \ \mu g/mL $ $ In Michae (Mistar/M), n = 10 \ or 12 $ $ Mice (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ or 12 $ $ Miter (Mistar/M), n = 10 \ o$				vitamin C, and NO level and MDA contents		proinflammatory mediators iNOS and IL-1 β Reduction in ulcer size	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	nar s	Rats (Wistar/M), $n = 5$	$12.5-400 \ \mu g/mL$	DPPH radical scavenging	LPS-induced subcutaneous inflammatory assay	Inhibition of DPPH radical and decrease in skin temperature and blood flow, reducing tissue inflammation process	Leelarungrayub et al. 2017 [50]
synthase; NO: nitric oxide; ROS: reactive oxygen species; SOD: superoxide dismutase; CAT: catalase; GPx: glutathione peroxidase; GSH: glutathione; GR: reductase glutathione; MDA: MH: 1,2-dimethyl hydrazine; LPO: lipid peroxides; iNOS: inducible nitric oxide synthase; IL-1 <i>β</i> : interleukin-1 beta; DPPH: 2,2-diphenyl-1-picrylhydrazyl radical; LPS: lipopolysaccharide; ⁻ azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); TC: total cholesterol; TC: triglycerides; LDL: low-density lipoprotein; VCAM-1: vascular cell adhesion molecule-1; MCP-1: monocyte -1 (MCP-1); NBT: nitroblue tetrazolium; TBARS: thiobarbituric acid; NF-κB: nuclear factor kappa B; MDA: malondialdehyde; CPT-11: irinotecan, Camptosar, Camptothecin-11; COX-2: F-α: tumor necrosis factor alpha; IL-6: interleukin-17; FRAP: ferric reducing antioxidant power; MPO: myeloperoxidase; TNBS: trinitrobenzenesulphonic acid; Nrf-2: roid 2-related factor 2; PMA: phorbol-12-myristate-13-acetate.	Е	Mice (C57B/6/M), $n = 10$ or 12	5 mg/day (p.o.), 15 days	Anthralin-induced ear edema model	Imiquimod-induced psoriasis	Improved inflammation and healing, on anthralin model and imiquimod	Pivetta et al. 2018 [53]
	with MH: MH: - azii 1 (h	ase; NO: nitric oxide; ROS: reactive 1,2-dimethyl hydrazine; LPO: lipid J to-bis(3-ethylbenzothiazoline-6-sulph fCP-1); NBT: nitroblue tetrazolium; rumor necrosis factor alpha; IL-6: int related factor 2; PMA: phorbol-12-1	 oxygen species, SOD: supe peroxides; iNOS: inducible r onic acid); TC: total cholest TBARS: thiobarbituric acid; cerleukin-6; IL-17: interleuki myristate-13-acetate. 	rroxide dismutase; CAT: catalas iitric oxide synthase; IL-1 <i>β</i> ; inte erol; TG: triglycerides; LDL: low NF-κB: nuclear factor kappa B; n-17; FRAP: ferric reducing ant	;; GPx: glutathione peroxi leukin-1 beta; DPPH: 2,2- -density lipoprotein; VCA MDA: malondialdehyde; oxidant power; MPO: mye	idase; GSH: glutathione; GR: red diphenyl-1-picrylhydrazyl radica M-1: vascular cell adhesion molo CPT-11: irinotecan, Camptosar, eloperoxidase; TNBS: trinitroben	uctase glutathione; MDA: 1, LPS: lipopolysaccharide; ccule-1; MCP-1: monocyte Camptothecin-11; COX-2: zenesulphonic acid; Nrf-2:

Continued.	
3:	
TABLE	



FIGURE 3: Methodological quality of included *in vivo* studies. White bars indicate the proportion of articles that met each criterion; black bars indicate the proportion of studies with unclear answers.

inflammation induced by biological and chemical agents; and atherosclerosis.

In recent years, some reports relate pathogen infection to the development and progression of chronic inflammation. In this systematic review, we found 9 studies reporting inflammatory conditions induced by microorganisms or their components, including LPS from E. coli, complete Freund's adjuvant, S. flexneri, and P. multocida [22, 31, 34, 36, 39, 40, 44, 50]. LPS is the major cause of endotoxemia and sepsis. Toll-like receptor 4 (TLR4) is the main way to activate the inflammation pathway. Some authors suggest that LPS would stimulate inflammation by stimulating the production of reactive oxygen species, mainly by the production of superoxide anion (O_2^{-}) ; these factors activate for example the MAPK pathway that will trigger cellular responses to increase the production of proinflammatory cytokines to evoke the immune system to fight the injury [44, 70].

In addition, administration of LPS or microorganisms induces transcription factor NF- κ B for initiating and sustaining inflammatory reactions. In the cell cytoplasm, NF- κ B is inactivated by the interaction with newly synthesized protein inhibitory κ B (I κ B), in the TLR4 signaling-promoted dissociation of complex I κ B-NF- κ B and translocation of NF- κ B into the nucleus from the cytoplasm to induce gene transcription of cytokines and chemokines [71].

Another widely used model corresponds to the evaluation of inflammatory bowel disease (IBD), for which several pharmacological models are employed, such as induction of ulcers by *S. flexneri* strains, intestinal mucositis induced by chemotherapy, and enterocolitis induced by DMH [40, 47, 51]. These pathologies are characterized by an excessive response of the immune system of the intestinal mucosa, activating the production and release of inflammatory mediators, such as eicosanoids, cytokines, reactive oxygen species (ROS), and nitrogen. In addition, defense cells such as mast cells produce toxic superoxide anions in the inflammatory environment and recruit neutrophils generating excess ROS, proteolytic enzymes, and ROS that contribute to lipid peroxidation. Furthermore, activated macrophages, neutrophils, and mast cells express receptors for IL-1 β and iNOS playing an important role in progression or persistence of intestinal lesion [72–74].

Involvement of inflammation in the pathogenesis of atherosclerosis is also well documented. Inflammatory cell types such as T-cells, monocytes, and neutrophils play major roles in mediating the inflammatory response in atherosclerosis. The deposition of lipid and oxidized low-density lipoprotein contributes to the initial and prolongated inflammatory response, especially in lipid oxidation, which is taken up by macrophages, dendritic cells, and smooth muscle cells to form lipid-laden foam cells. In addition, cells of the immune system participate to the inflammatory process producing proinflammatory cytokines IL-1 and TNF- α , mediators associated with reactive oxygen species- (ROS-) and nitric oxide- (NO-) (in excess) induced expression of adhesion molecules, and potentiate inflammation within the atherosclerotic lesion, which induces the chemoattraction of defense cells [49, 75–77].

Other experimental models have been well reported to assess chronic inflammation, such as cotton-pellet-induced granuloma, subcutaneous air pouch, and formalin test. However, these tests present low similarity to the previously described models in relation to the ability to resemble specific human inflammations, since they reproduce the general aspects of the chronic inflammatory process [26, 33, 35, 38].

The formalin test is commonly described in acute inflammation tests; however, repeated application was described in the studies of Jeena et al. [26, 35]. The inflammatory process is a result of tissue and functional alterations in the tissue accompanied by the release of inflammatory mediators such as histamine, prostaglandins, nitric oxide, and cytokines. To evaluate this, the authors monitor the reduction of edema and perform dosage of the involved mediators [26, 35, 78, 79].

The granulomatous tissue induced by the subcutaneous cotton implant is a widely used method for the assessment of anti-inflammatory substance in chronic inflammation. This type of inflammation is a result of several infectious, autoimmune, toxic, allergic, and neoplastic conditions, characterized by the presence of mononuclear leukocytes, specifically macrophages, which respond to several chemical mediators of cell damage, most often forming multinucleated giant cells. In the injured tissue, some histological patterns are observed, such as edema, neovascularization, and early-stage fibrosis [80, 81].

3.6. Role of Antioxidants in Chronic Inflammation. Free radicals correspond to a molecule or atom that carries unpaired electrons that makes them highly reactive and unstable and can cause cell damage. In normal cell metabolism, many free radicals are produced, which serve important functions in the signaling of specific pathophysiological pathways, the great majority of these radicals being produced in the mitochondrial metabolism. Examples of these are hydroxyl radical, superoxide anion, hydrogen peroxide, and organic peroxides. In addition, in the absence or low concentrations of oxygen, excessive lipid peroxidation occurs and mitochondria also generate nitric oxide (NO), which can generate reactive nitrogen species, which can produce other reactive species such as malondialdehyde [11, 82, 83].

In the inflammatory process, defensive cells located in injured regions lead to a "respiratory burst" in the tissue resulting from increased uptake of oxygen and, therefore, increased production and release of ROS in the damaged area. The release of mediators by these cells associated with the presence of ROS and RNS stimulates signal transduction cascades and alters transcription factors, such as NF- κ B, which mediate vital reactions of cellular stress, leading to expression of COX-2, iNOS, and proinflammatory cytokines. Metabolites generated in inflammation associated with oxidative stress impair healthy tissue by altering the stroma and surrounding epithelial cells, which after a long period of time can evolve into more serious problems and trigger, for example, carcinogenesis [84, 85].

In general, the body has an enzymatic system to combat the damage caused by oxidative stress. Three major antioxidants are the first line of defense against oxidative stress: superoxide dismutase, catalase, and glutathione peroxidase, being antioxidants commonly measured in the investigation of the antioxidant activity of natural compounds [86, 87].

SOD enzyme, which converts highly reactive superoxide radicals in hydrogen peroxide (H_2O_2) and molecular oxygen [86], performs a first antioxidant defense in an oxidative stress situation [88]. Catalase also participates in this defense process, catalyzing the conversion of hydrogen peroxide (highly reactive) to water and molecular oxygen, being located mainly in the peroxisomes [89]. Glutathione exists in two forms with different subunits and different active sites. Glutathione peroxidase catalyzes the reduction of H_2O_2 or organic peroxides (ROOH) to water or alcohol by the presence of GSH, which is converted to oxidize glutathione during this reaction. The main function of this latter enzyme is the protection of the polyunsaturated cell membranes [87].

In the articles reported in this study, the authors correlated the antioxidant tests with the anti-inflammatory activity of the essential oils and substances tested. For this, isolated tests of in vitro antioxidant activity, such as DPPH, inhibition of β -carotene degradation, ABTS, NO, and FRAP tests, were used as initial screening of the pharmacological activity of EOs or isolated substances. Based on the satisfactory results obtained, some anti-inflammatory activity tests were subsequently conducted [24, 27, 29-31, 40, 48, 50]. In contrast, other studies, especially in vivo studies, assessed the anti-inflammatory activity and at the end of the experiment the animals were euthanized and blood collected for serum levels indicating enzymes of oxidative stress. In these models, the analyses of superoxide dismutase, catalase, glutathione, malondialdehyde, and lipid peroxidation were mostly described [25, 26, 32, 35, 36, 39, 46, 47, 49].

3.7. Essential Oils with Antioxidant Properties in the Treatment of Chronic Inflammation. In view of the wide use of traditional medicine associated with its importance in drug discovery, EOs have been studied and their compounds identified/isolated components due to their diverse pharmacological properties, including the treatment of acute and chronic inflammation justified by their antioxidant properties [16, 17]. EOs are volatile compounds that may contain more than 300 different compounds. Most of chemical constituents are terpenes, especially mono- and sesquiterpenes, but some nonterpene compounds biosynthesized by the phenylpropanoid pathway can also be present in EOs [14]. Figure 4 shows the major constituents of the EOs reported in this study, and Figure 5 shows the isolated constituents with antioxidant activity tested in chronic inflammation models.

The anti-inflammatory and antioxidant activities of species and natural compounds were reported in the studies included in this article, where numerous preclinical cstudies presented promising results. In the experiments using peritoneal macrophages (Raw 264.7, *in vitro*), EOs obtained from *O. crocata*, *O. quixo*, *C. intratropica*, *C. reticulata*, *H. sabdariffa*, *C. obtusa*, and *C. aurantium* were able to



FIGURE 4: Chemical structure of the major constituents of the essential oils evaluated as antioxidant and anti-inflammatory in chronic inflammation.

reduce the levels of ROS considerably reducing tissue inflammation and RNS that cause tissue damage. In addition, EO of *H. sabdariffa* and *C. aurantium* inhibited NF- κ B and MAPK signaling and promoted the decrease in the expression of transcription factors for the production of cytokines IL-1 β , IL-6, and TNF- α . In addition, these EOs decreased the expression of cyclooxygenase-2 and iNOS enzymes [28, 30, 41, 42, 48].

In vivo tests indicated that the treatment with ginger and *P. nigrum* EOs presents the ability to sequester superoxide, DPPH, and hydroxyl radicals, in addition to inhibiting lipid peroxidation, associated with the reduction in edema induced by chronic administration of formalin in paw tissue. In this way, the decrease in the inflammatory process occurs due to the increase in the activity of antioxidant enzymes SOD and glutathione [26, 35]. In contrast, *C. aurantium*



FIGURE 5: Chemical structure of the constituents isolated of the essential oils evaluated as antioxidant and anti-inflammatory in chronic inflammation.

and *C. ternata* reduced defense cell migration and edema and reduced the levels of nitric oxide in the inflammatory exudate in a granuloma model. In inflammation induced by biological agents such as *E. coli* LPS, treatment with EO of *N. sativa* increased SOD and CAT expression and reduced nitric oxide and malondialdehyde levels [29, 33].

P. integerrima presented potential antiasthmatic activity in preclinical studies. This activity is related to inhibition of the degranulation of mast cell and inhibition of 5-LOX, where treatment with EO considerably reduced the number of total leukocytes in bronchoalveolar lavage fluid and pulmonary levels of myeloperoxidase. Associated with this, the plant presented antioxidant potential in the DPPH test, indicating satisfactory results for the treatment of chronic pulmonary diseases with possible involvement of oxidative pathways [31].

Articles that report the pharmacological evaluation of the essential oil of *Z. cassumunar* in encapsulated niosome by

therapeutic ultrasound were also found in the searches. The encapsulated niosomes were applied in the skin and subsequently evaluated using ultrasound therapy to potentiate the anti-inflammatory action of the EO, favoring the absorption by the skin and subsequent action on the inflammation induced by repeated administration of LPS. The antiinflammatory action of this oil is probably related to the presence of sabinene and terpinen-4-ol (major compounds) which reduce the expression of NF- κ B and interleukin-6. The antioxidant tests indicated antioxidant activity of the EO, which inhibited DPPH radical, demonstrating once again the relation of inflammatory processes and antioxidant mechanisms [50].

In relation to the majority compounds studied, most are classified as monoterpenes, such as carvacrol, thymol, L-carveol, L-carvone, and m-cymene (Figure 6).

The carvacrol (5-isopropyl-2-methylphenol) is a phenolic monoterpene present in EOs of various species especially



FIGURE 6: Molecular mechanisms of action of essential oils activity mediating signaling involving inhibition of NF- κ B, MAPK, and decreased intracellular oxidative stress.

the Lamiaceae family, which presented pharmacological potentials, such as antioxidant and anti-inflammatory [90, 91]. The compound was the most reported in the studies included in this article, exhibiting activity in preclinical models of inflammatory diseases of the gastrointestinal tract, such as chemotherapy-induced mucositis and DMH-induced colitis. Its pharmacological activity in the mentioned models is a result of reduced expression of NF- κ B, COX-2, and iNOS, associated with decreased levels of IL-1 β , TNF- α , and NO. The treatment was also able to increase the antioxidant enzymes SOD, CAT, MDA, and GSH [47, 51].

Anethole (1-methoxy-4-benzene-[1-propenyl]) is an aromatic compound used in the industry, which has antioxidant, antibacterial, antifungal, and anti-inflammatory potential [92, 93]. Oral treatment with anethole inhibited complete Freund adjuvant-induced paw edema, in addition to reducing myeloperoxidase levels, TNF- α , IL-1 β , and IL-17, thereby reducing the levels of ROS in the injured tissue [25].

Another terpene described in the articles was linalool (3,7-dimethylocta-1,6-dien-3-ol), which was investigated to assess its ability to reduce *P. multocida*-induced lung inflammation. Repeated subcutaneous administration of linalool reduced the levels of TNF- α and IL-6 and the number of polymorphs (neutrophils) in lung tissue, associated with an increase in SOD [34, 94]. Eucalyptol (1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane) was also evaluated in a model of chronic lung inflammation induced by

repeated exposure to cigarette smoke, where the treatment reduced the expression of NF- κ B and consequently the levels of proinflammatory cytokines, promoting the reduction of the presence of leukocytes in the pulmonary alveoli. The levels of antioxidant enzymes SOD, CAT, MDA, and GSH, as well as total ROS were reduced [46].

In the experimental models, cinnamaldehyde, β -elemene, and thymol were evaluated in LPS-induced cardiac inflammation or hyperlipidic diet. Cinnamaldehyde possesses potent anti-inflammation effects on endotoxemia [94]. Zhao et al. [44] showed that cinnamaldehyde inhibited inflammatory infiltration and the levels of TNF- α , IL-1 β , and IL-6 in LPS-stimulated rats by blocking the TLR4 and MAPK pathways, associated with the reduction in ROS levels in cardiac tissue [44]. β -Elemene also showed activity in the cardiac inflammation model. In this evaluation, treatment of apolipoprotein E (ApoE) knockout mice with β -elemene inhibited atherosclerotic lesions by reducing levels of nitric oxide, cytokines, and oxidative stress indicators and reversing the intracellular ROS production and MAPK signaling activation [49].

Thymol (2-isopropyl-5-methylphenol) was evaluated in two different models, inflammation in aortic intimal and imiquimod-induced psoriasis. In the first model, the antioxidant tests were evaluated *in vitro* DPPH and ABTS radical scavenging assay, demonstrating high antioxidant activity. The treatment also reduced lipid peroxidation *in vivo*, reducing serum levels of malondialdehyde. In relation to the parameters of anti-inflammatory activity, thymol reduced the expression of vascular adhesion molecules (VCAM), thus reducing leukocyte migration and proinflammatory cytokines [45]. Thus, the results suggest that this monoterpene reduced the oxidative stress, the putative mechanism involved in the pathogenesis of endothelial dysfunction, an early key event in the progression of atherosclerosis [95].

Nanoparticles containing thymol were also evaluated, using experimental models that mimic psoriasis. For this, anthralin (1,8-dihydroxy-9-anthrone), a drug used to treat psoriasis, was used for inducing inflammation in healthy skin mice and the antioxidant activity was evaluated after exposition to light, generators, and oxidative stress events. Thymol in nanoparticles showed better inhibition of edema by reducing inflammatory cells in inflamed tissue when compared to free thymol, indicating that nanoparticles improve antiinflammatory activity mediated by mechanisms that inhibit the formation of reactive oxygen species [53, 96].

In general, the results of the studies indicated that EOs and/or their compounds presented pharmacological properties through the blockade of mitogen-activated protein kinase (MAPK) pathways, blocking NF- κ B activation by mechanisms associated with the reduction of oxidative stress, leading to the reduction in the production of several proinflammatory mediators (Figure 6).

4. Conclusion and Perspectives

This systematic review suggests that EOs and their major compounds have a potential for the treatment of inflammatory diseases especially in chronic inflammatory conditions. The main action targets presented in this review for the therapy of chronic inflammations were the reduction in reactive oxygen and nitrogen species and the reduction in NF- κ B reducing the expression of proinflammatory cytokines.

In vivo tests reported various models of inflammation that resemble human pathologies, including assessment of their mechanism of action, antioxidant enzyme dosages, and molecular effects of EOs. Regarding the rigor of design and study data included in this review, most of the studies presented moderate quality indicating that some aspects still need to be improved but in general provide evidence of the anti-inflammatory potential associated with the antioxidant activity of EOs.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The authors acknowledge the financial support from the Brazilian agencies CNPq, CAPES, FACEPE, and State University of Feira de Santana (UEFS).

References

- E. Kolaczkowska and P. Kubes, "Neutrophil recruitment and function in health and inflammation," *Nature Reviews Immunology*, vol. 13, no. 3, pp. 159–175, 2013.
- [2] D. B. Vendramini-Costa and J. E. Carvalho, "Molecular link mechanisms between inflammation and cancer," *Current Pharmaceutical Design*, vol. 18, no. 26, pp. 3831–3852, 2012.
- [3] S. I. Hammerschmidt, M. Ahrendt, U. Bode et al., "Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo," *Journal of Experimental Medicine*, vol. 205, no. 11, pp. 2483–2490, 2008.
- [4] J. Kodydkova, L. Vavrova, B. Stankova, J. Macasek, T. Krechler, and A. Zak, "Antioxidant status and oxidative stress markers in pancreatic cancer and chronic pancreatitis," *Pancreas*, vol. 42, no. 4, pp. 614–621, 2013.
- [5] M. E. Ahmed, M. M. Khan, H. Javed et al., "Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer's type," *Neurochemistry International*, vol. 62, no. 4, pp. 492–501, 2013.
- [6] Q. Zhang, J. J. Zhao, J. Xu, F. Feng, and W. Qu, "Medicinal uses, phytochemistry and pharmacology of the genus Uncaria," Journal of Ethnopharmacology, vol. 173, pp. 48–80, 2015.
- [7] S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, inflammation and cancer," *Cell*, vol. 140, no. 6, pp. 883–899, 2010.
- [8] J. K. Kundu and Y. J. Surh, "Emerging avenues linking inflammation and cancer," *Free Radical Biology & Medicine*, vol. 52, no. 9, pp. 2013–2037, 2012.
- [9] A. Gomes, E. Fernandes, J. Lima, L. Mira, and M. Corvo, "Molecular mechanisms of anti-inflammatory activity mediated by flavonoids," *Current Medicinal Chemistry*, vol. 15, no. 16, pp. 1586–1605, 2008.
- [10] J. Fang, T. Seki, and H. Maeda, "Therapeutic strategies by modulating oxygen stress in cancer and inflammation," *Advanced Drug Delivery Reviews*, vol. 61, no. 4, pp. 290–302, 2009.
- [11] S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, "Oxidative stress, inflammation, and cancer: how are they linked?," *Free Radical Biology & Medicine*, vol. 49, no. 11, pp. 1603–1616, 2010.
- [12] A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio, "Chronic inflammation and oxidative stress in human carcinogenesis," *International Journal of Cancer*, vol. 121, no. 11, pp. 2381–2386, 2007.
- [13] Y. Wu, S. Antony, J. L. Meitzler, and J. H. Doroshow, "Molecular mechanisms underlying chronic inflammation-associated cancers," *Cancer Letters*, vol. 345, no. 2, pp. 164–173, 2014.
- [14] P. Rubiolo, B. Sgorbini, E. Liberto, C. Cordero, and C. Bicchi, "Essential oils and volatiles: sample preparation and analysis. A review," *Flavour and Fragrance Journal*, vol. 25, no. 5, pp. 282–290, 2010.
- [15] C. Bicchi, E. Liberto, M. Matteodo et al., "Quantitative analysis of essential oils: a complex task," *Flavour and Fragrance Journal*, vol. 23, no. 6, pp. 382–391, 2008.
- [16] F. Bakkali, S. Averbeck, D. Averbeck, and M. Idaomar, "Biological effects of essential oils – a review," *Food and Chemical Toxicology*, vol. 46, no. 2, pp. 446–475, 2008.
- [17] M. G. Miguel, "Antioxidant and anti-inflammatory activities of essential oils: a short review," *Molecules*, vol. 15, no. 12, pp. 9252–9287, 2010.

- [18] E. J. Lenardão, L. Savegnago, R. G. Jacob, F. N. Victoria, and D. M. Martinez, "Antinociceptive effect of essential oils and their constituents: an update review," *Journal of the Brazilian Chemical Society*, vol. 27, no. 3, pp. 435–474, 2016.
- [19] L. L. Silva, Q. I. Garlet, S. C. Benovit et al., "Sedative and anesthetic activities of the essential oils of *Hyptis mutabilis* (Rich.) Briq. and their isolated components in silver catfish (*Rhamdia quelen*)," *Brazilian Journal of Medical and Biological Research*, vol. 46, no. 9, pp. 771–779, 2013.
- [20] L. M. Lopes Campêlo, C. Gonçalves e Sá, A. A. de Almeida et al., "Sedative, anxiolytic and antidepressant activities of *Citrus limon* (Burn) essential oil in mice," *Die Pharmazie*, vol. 66, no. 8, pp. 623–627, 2011.
- [21] C. R. Hooijmans, M. M. Rovers, R. B. M. de Vries, M. Leenaars, M. Ritskes-Hoitinga, and M. W. Langendam, "SYRCLE's risk of bias tool for animal studies," *BMC Medical Research Methodology*, vol. 14, no. 1, p. 43, 2014.
- [22] P. S. Siqueira-Lima, J. C. Silva, J. S. S. Quintans et al., "Natural products assessed in animal models for orofacial pain – a systematic review," *Revista Brasileira de Farmacognosia*, vol. 27, no. 1, pp. 124–134, 2017.
- [23] X. Zeng, Y. Zhang, J. S. W. Kwong et al., "The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review," *Journal of Evidence Based Medicine*, vol. 8, no. 1, pp. 2–10, 2015.
- [24] M. L. Tsai, C. C. Lin, W. C. Lin, and C. H. Yang, "Antimicrobial, antioxidant and anti-inflammatory activities of essential oils from five selected herbs," *Bioscience, Biotechnology, and Biochemistry*, vol. 75, no. 10, pp. 1977–1983, 2014.
- [25] A. M. V. Ritter, T. P. Domiciano, W. A. Verri et al., "Antihypernociceptive activity of anethole in experimental inflammatory pain," *Inflammopharmacology*, vol. 21, no. 2, pp. 187–197, 2013.
- [26] K. Jeena, V. B. Liju, and R. Kuttan, "Antioxidant, antiinflammatory and antinociceptive activities of essential oil from ginger," *Indian Journal of Physiology and Pharmacology*, vol. 57, no. 1, pp. 51–62, 2013.
- [27] M. Z. El-Readi, H. H. Eid, M. L. Ashour et al., "Variations of the chemical composition and bioactivity of essential oils from leaves and stems of *Liquidambar styraciflua* (Altingiaceae)," *Journal of Pharmacy and Pharmacology*, vol. 65, no. 11, pp. 1653–1663, 2013.
- [28] J. Valente, M. Zuzarte, M. J. Gonçalves et al., "Antifungal, antioxidant and anti-inflammatory activities of *Oenanthe crocata* L. essential oil," *Food and Chemical Toxicology*, vol. 62, pp. 349–354, 2013.
- [29] J. Lin, Q. Y. Cai, W. Xu, J. M. Lin, and J. Peng, "Chemical composition, anticancer, anti-neuroinflammatory, and antioxidant activities of the essential oil of *Patrinia scabiosaefolia*," *Chinese Journal of Integrative Medicine*, vol. 24, no. 3, pp. 207–212, 2018.
- [30] R. A. Destryana, D. G. Young, C. L. Woolley, T.-C. Huang, H.-Y. Wu, and W.-L. Shih, "Antioxidant and antiinflammation activities of Ocotea, Copaiba and Blue Cypress essential oils in vitro and in vivo," *Journal of the American Oil Chemists' Society*, vol. 91, no. 9, pp. 1531–1542, 2014.
- [31] R. L. Shirole, N. L. Shirole, A. A. Kshatriya, R. Kulkarni, and M. N. Saraf, "Investigation into the mechanism of action of essential oil of *Pistacia integerrima* for its antiasthmatic activity," *Journal of Ethnopharmacology*, vol. 153, no. 3, pp. 541–551, 2014.

- [32] N. R. Patil, V. P. Rasal, and R. H. Malabade, "Screening of mandarin oil on indomethcin induced inflammatory bowel disease in wistar rats," *Indian Journal of Pharmaceutical Education and Research*, vol. 48, Supplementary, pp. 1–6, 2014.
- [33] P. Khodabakhsh, H. Shafaroodi, and J. Asgarpanah, "Analgesic and anti-inflammatory activities of *Citrus aurantium* L. blossoms essential oil (neroli): involvement of the nitric oxide/ cyclic-guanosine monophosphate pathway," *Journal of Natural Medicines*, vol. 69, no. 3, pp. 324–331, 2015.
- [34] Q. Wu, L. Yu, J. Qiu et al., "Linalool attenuates lung inflammation induced by *Pasteurella multocida* via activating Nrf-2 signaling pathway," *International Immunopharmacology*, vol. 21, no. 2, pp. 456–463, 2014.
- [35] K. Jeena, V. B. Liju, N. P. Umadevi, and R. Kuttan, "Antioxidant, anti-inflammatory and antinociceptive properties of black pepper essential oil (*Piper nigrum Linn*)," *Journal of Essential Oil Bearing Plants*, vol. 17, no. 1, pp. 1–12, 2014.
- [36] E. Entok, M. C. Ustuner, C. Ozbayer et al., "Anti-inflammatuar and anti-oxidative effects of *Nigella sativa* L.: ¹⁸FDG-PET imaging of inflammation," *Molecular Biology Reports*, vol. 41, no. 5, pp. 2827–2834, 2014.
- [37] M. Kazemi, "Chemical composition and antimicrobial, antioxidant activities and anti-inflammatory potential of *Achillea millefolium* L., *Anethum graveolens* L., and *Carum copticum* L. essential oils," *Journal of Herbal Medicine*, vol. 5, no. 4, pp. 217–222, 2015.
- [38] M. M. G. Pinheiro, A. B. Miltojević, N. S. Radulović, I. R. Abdul-Wahab, F. Boylan, and P. D. Fernandes, "Antiinflammatory activity of *Choisya ternata* Kunth essential oil, ternanthranin, and its two synthetic analogs (methyl and propyl *N*-methylanthranilates)," *PLoS One*, vol. 10, no. 3, article e0121063, 2015.
- [39] M. Kara, S. Uslu, F. Demirci, H. E. Temel, and C. Baydemir, "Supplemental carvacrol can reduce the severity of inflammation by influencing the production of mediators of inflammation," *Inflammation*, vol. 38, no. 3, pp. 1020–1027, 2015.
- [40] N. G. Allam, E. A. E. A. Eldrieny, and A. Z. Mohamed, "Effect of combination therapy between thyme oil and ciprofloxacin on ulcer-forming *Shigella flexneri*," *The Journal of Infection in Developing Countries*, vol. 9, no. 05, pp. 486–495, 2015.
- [41] C. Y. Shen, T. T. Zhang, W. L. Zhang, and J. G. Jiang, "Antiinflammatory activities of essential oil isolated from the calyx of *Hibiscus sabdariffa* L," *Food & Function*, vol. 7, no. 10, pp. 4451–4459, 2016.
- [42] Y. Park, S. A. Yoo, W. U. Kim, C. S. Cho, J. M. Woo, and C. H. Yoon, "Anti-inflammatory effects of essential oils extracted from *Chamaecyparis obtusa* on murine models of inflammation and RAW 264.7 cells," *Molecular Medicine Reports*, vol. 13, no. 4, pp. 3335–3341, 2016.
- [43] E. Skała, P. Rijo, C. Garcia et al., "The essential oils of *Rhapon-ticum carthamoides* hairy roots and roots of soil-grown plants: chemical composition and antimicrobial, anti-inflammatory, and antioxidant activities," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 8505384, 10 pages, 2016.
- [44] H. Zhao, M. Zhang, F. Zhou et al., "Cinnamaldehyde ameliorates LPS-induced cardiac dysfunction via TLR4-NOX4 pathway: the regulation of autophagy and ROS production," *Journal of Molecular and Cellular Cardiology*, vol. 101, pp. 11–24, 2016.
- [45] Y. M. Yu, T. Y. Chao, W. C. Chang, M. J. Chang, and M. F. Lee, "Thymol reduces oxidative stress, aortic intimal thickening, and inflammation-related gene expression in hyperlipidemic

rabbits," Journal of Food and Drug Analysis, vol. 24, no. 3, pp. 556–563, 2016.

- [46] E. Kennedy-Feitosa, R. T. Okuro, V. Pinho Ribeiro et al., "Eucalyptol attenuates cigarette smoke-induced acute lung inflammation and oxidative stress in the mouse," *Pulmonary Pharmacology & Therapeutics*, vol. 41, pp. 11–18, 2016.
- [47] E. M. Alvarenga, L. K. M. Souza, T. S. L. Araújo et al., "Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation," *Chemico-Biological Interactions*, vol. 260, pp. 129–140, 2016.
- [48] C. Y. Shen, J. G. Jiang, W. Zhu, and Q. Ou-Yang, "Antiinflammatory effect of essential oil from *Citrus aurantium L.* var. *amara* Engl," *Journal of Agricultural and Food Chemistry*, vol. 65, no. 39, pp. 8586–8594, 2017.
- [49] M. Liu, X. Chen, J. Ma et al., "β-Elemene attenuates atherosclerosis in apolipoprotein E-deficient mice via restoring NO levels and alleviating oxidative stress," *Biomedicine & Pharmacotherapy*, vol. 95, pp. 1789–1798, 2017.
- [50] J. Leelarungrayub, J. Manorsoi, and A. Manorsoi, "Antiinflammatory activity of niosomes entrapped with Plai oil (*Zingiber cassumunar* Roxb.) by therapeutic ultrasound in a rat model," *International Journal of Nanomedicine*, vol. 12, pp. 2469–2476, 2017.
- [51] K. Arigesavan and G. Sudhandiran, "Carvacrol exhibits antioxidant and anti-inflammatory effects against 1, 2-dimethyl hydrazine plus dextran sodium sulfate induced inflammation associated carcinogenicity in the colon of Fischer 344 rats," *Biochemical and Biophysical Research Communications*, vol. 461, no. 2, pp. 314–320, 2015.
- [52] F. M. Marques, M. M. Figueira, E. F. P. Schmitt et al., "In vitro anti-inflammatory activity of terpenes via suppression of superoxide and nitric oxide generation and the NF-κB signalling pathway," *Inflammopharmacology*, pp. 1–9, 2018.
- [53] T. P. Pivetta, S. Simões, M. M. Araújo, T. Carvalho, C. Arruda, and P. D. Marcato, "Development of nanoparticles from natural lipids for topical delivery of thymol: investigation of its anti-inflammatory properties," *Colloids and Surfaces B: Biointerfaces*, vol. 164, pp. 281–290, 2018.
- [54] D. H. S. Silva, I. Castro-Gamboa, and V. D. S. Bolzani, "Plant diversity from Brazilian Cerrado and Atlantic Forest as a tool for prospecting potential therapeutic drugs," in *Comprehensive Natural Products II Chemistry and Biology, Vol. 3*, R. Verpoorte, Ed., pp. 95–133, Elsevier, Oxford, UK, 2010.
- [55] A. L. Harvey, R. Edrada-Ebel, and R. J. Quinn, "The re-emergence of natural products for drug discovery in the genomics era," *Nature Reviews Drug Discovery*, vol. 14, no. 2, pp. 111–129, 2015.
- [56] C. Sheridan, "Recasting natural product research," *Nature Biotechnology*, vol. 30, no. 5, pp. 385–387, 2012.
- [57] P. Balachandran and R. Govindarajan, "Ayurvedic drug discovery," *Expert Opinion on Drug Discovery*, vol. 2, no. 12, pp. 1631–1652, 2007.
- [58] W. Y. Wu, J. J. Hou, H. L. Long, W. Z. Yang, J. Liang, and D. A. Guo, "TCM-based new drug discovery and development in China," *Chinese Journal of Natural Medicines*, vol. 12, no. 4, pp. 241–250, 2014.
- [59] J. E. de Aguilar-Nascimento, "Fundamental steps in experimental design for animal studies," *Acta Cirurgica Brasileira*, vol. 20, no. 1, pp. 2-3, 2005.

- [60] J. A. Hirst, J. Howick, J. K. Aronson et al., "The need for randomization in animal trials: an overview of systematic reviews," *PLoS One*, vol. 9, no. 6, article e98856, 2014.
- [61] R. Medzhitov and C. A. Janeway Jr., "Innate immunity: the virtues of a nonclonal system of recognition," *Cell*, vol. 91, no. 3, pp. 295–298, 1997.
- [62] N. Fujiwara and K. Kobayashi, "Macrophages in inflammation," Current Drug Targets - Inflammation & Allergy, vol. 4, no. 3, pp. 281–286, 2005.
- [63] A. Ariel and C. N. Serhan, "New lives given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the resolution of inflammation," *Frontiers in Immunology*, vol. 3, 2012.
- [64] U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal, "Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents," *Clinical Chemistry*, vol. 51, no. 12, pp. 2252–2256, 2005.
- [65] N. Esser, N. Paquot, and A. J. Scheen, "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease," *Expert Opinion on Investigational Drugs*, vol. 24, no. 3, pp. 283–307, 2015.
- [66] S. Epelman, K. J. Lavine, and G. J. Randolph, "Origin and functions of tissue macrophages," *Immunity*, vol. 41, no. 1, pp. 21–35, 2014.
- [67] C. Nathan and A. Ding, "Nonresolving inflammation," *Cell*, vol. 140, no. 6, pp. 871–882, 2010.
- [68] M. Murakami and T. Hirano, "The molecular mechanisms of chronic inflammation development," *Frontiers in Immunol*ogy, vol. 3, 2012.
- [69] E. S. Huseby, P. G. Huseby, S. Shah, R. Smith, and B. D. Stadinski, "Pathogenic CD8 T cells in multiple sclerosis and its experimental models," *Frontiers in Immunology*, vol. 3, 2012.
- [70] H. Park, J. Chun, H. Jung, C. Choi, and Y. Bae, "Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells," *Cardio*vascular Research, vol. 72, no. 3, pp. 447–455, 2006.
- [71] J. Sakai, E. Cammarota, J. A. Wright et al., "Lipopolysaccharideinduced NF- κ B nuclear translocation is primarily dependent on MyD88, but TNF α expression requires TRIF and MyD88," *Scientific Reports*, vol. 7, no. 1, p. 1428, 2017.
- [72] C. A. Dinarello, "A clinical perspective of IL-1β as the gatekeeper of inflammation," *European Journal of Immunology*, vol. 41, no. 5, pp. 1203–1217, 2011.
- [73] G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk, and J. L. Wallace, "Hapten-induced model of chronic inflammation and ulceration in the rat colon," *Gastroenterology*, vol. 96, no. 3, pp. 795–803, 1989.
- [74] A. Abe, H. Fukui, S. Fujii et al., "Role of Necl-5 in the pathophysiology of colorectal lesions induced by dimethylhydrazine and/or dextran sodium sulphate," *Journal of Pathology*, vol. 217, no. 1, pp. 42–53, 2009.
- [75] Y. Mizuno, R. F. Jacob, and R. P. Mason, "Inflammation and the development of atherosclerosis," *Journal of Atherosclerosis* and Thrombosis, vol. 18, no. 5, pp. 351–358, 2011.
- [76] P. Libby, "Inflammation in atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2045– 2051, 2012.
- [77] B. W. Wong, A. Meredith, D. Lin, and B. M. McManus, "The biological role of inflammation in atherosclerosis," *Canadian Journal of Cardiology*, vol. 28, no. 6, pp. 631–641, 2012.

- [78] S. Hunskaar and K. Hole, "The formalin test in mice: dissociation between inflammatory and non-inflammatory pain," *Pain*, vol. 30, no. 1, pp. 103–114, 1987.
- [79] M. A. Martins, L. de Castro Bastos, and C. R. Tonussi, "Formalin injection into knee joints of rats: pharmacologic characterization of a deep somatic nociceptive model," *The Journal of Pain*, vol. 7, no. 2, pp. 100–107, 2006.
- [80] S. Mukhopadhyay, B. E. Wilcox, J. L. Myers et al., "Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules," *Chest*, vol. 144, no. 3, pp. 813–824, 2013.
- [81] K. K. Shah, B. S. Pritt, and M. P. Alexander, "Histopathologic review of granulomatous inflammation," *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, vol. 7, pp. 1–12, 2017.
- [82] R. O. Poyton, K. A. Ball, and P. R. Castello, "Mitochondrial generation of free radicals and hypoxic signaling," *Trends in Endocrinology and Metabolism*, vol. 20, no. 7, pp. 332–340, 2009.
- [83] P. Arulselvan, M. T. Fard, W. S. Tan et al., "Role of antioxidants and natural products in inflammation," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 5276130, 15 pages, 2016.
- [84] K. H. Han, N. Hashimoto, and M. Fukushima, "Relationships among alcoholic liver disease, antioxidants, and antioxidant enzymes," *World Journal of Gastroenterology*, vol. 22, no. 1, pp. 37–49, 2016.
- [85] B. A. Aslani and S. Ghobadi, "Studies on oxidants and antioxidants with a brief glance at their relevance to the immune system," *Life Sciences*, vol. 146, pp. 163–173, 2016.
- [86] W. Wang, M. X. Xia, J. Chen, R. Yuan, F. N. Deng, and F. F. Shen, "Gene expression characteristics and regulation mechanisms of superoxide dismutase and its physiological roles in plants under stress," *Biochemistry*, vol. 81, no. 5, pp. 465– 480, 2016.
- [87] B. H. Xiao, M. Shi, H. Chen et al., "Glutathione peroxidase level in patients with vitiligo: a meta-analysis," *BioMed Research International*, vol. 2016, Article ID 3029810, 11 pages, 2016.
- [88] A. Anju, J. Jeswin, P. C. Thomas, M. P. Paulton, and K. K. Vijayan, "Molecular cloning, characterization and expression analysis of cytoplasmic Cu/Zn-superoxid dismutase (SOD) from pearl oyster *Pinctada fucata*," *Fish & Shellfish Immunology*, vol. 34, no. 3, pp. 946–950, 2013.
- [89] M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur, "Free radicals, metals and antioxidants in oxidative stressinduced cancer," *Chemico-Biological Interactions*, vol. 160, no. 1, pp. 1–40, 2006.
- [90] K. C. Baser, "Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils," *Current Pharmaceutical Design*, vol. 14, no. 29, pp. 3106–3119, 2008.
- [91] A. G. Guimarães, G. F. Oliveira, M. S. Melo et al., "Bioassayguided evaluation of antioxidant and antinociceptive activities of carvacrol," *Basic & Clinical Pharmacology & Toxicology*, vol. 107, no. 6, pp. 949–957, 2010.
- [92] R. S. Freire, S. M. Morais, F. E. A. Catunda-Junior, and D. C. S. N. Pinheiro, "Synthesis and antioxidant, anti-inflammatory and gastroprotector activities of anethole and related compounds," *Bioorganic & Medicinal Chemistry*, vol. 13, no. 13, pp. 4353–4358, 2005.

- [93] I. Kosalec, S. Pepeljnjak, and D. Kustrak, "Antifungal activity of fluid extract and essential oil from anise fruits (*Pimpinella anisum* L., *Apiaceae*)," *Acta Pharmaceutica*, vol. 55, no. 4, pp. 377–385, 2005.
- [94] M. Huo, X. Cui, J. Xue et al., "Anti-inflammatory effects of linalool in RAW 264.7 macrophages and lipopolysaccharideinduced lung injury model," *Journal of Surgical Research*, vol. 180, no. 1, pp. e47–e54, 2013.
- [95] S. J. F. Mendes, F. I. A. B. Sousa, D. M. S. Pereira et al., "Cinnamaldehyde modulates LPS-induced systemic inflammatory response syndrome through TRPA1-dependent and independent mechanisms," *International Immunopharmacology*, vol. 34, pp. 60–70, 2016.
- [96] D. Harrison, K. K. Griendling, U. Landmesser, B. Hornig, and H. Drexler, "Role of oxidative stress in atherosclerosis," *The American Journal of Cardiology*, vol. 91, no. 3, pp. 7–11, 2003.



The Scientific World Journal

Journal of Immunology Research



Research and Practice











BioMed Research International



PPAR Research

Journal of Ophthalmology



Computational and Mathematical Methods in Medicine



International



Behavioural Neurology



Evidence-Based Complementary and Alternative Medicine







Research and Treatment



Journal of Oncology



Oxidative Medicine and Cellular Longevity



Submit your manuscripts at www.hindawi.com